Jump to content

Search the Community

Showing results for tags 'PBAC'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


    • Announcements, meetings and other resources
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...

Date Created

  • Start


Last Updated

  • Start


Filter by number of...

Found 10 results

  1. This is a platform for you to find tools and resources to help you have a voice in Australia's healthcare decision making processes. Consumer Comments for the March PBAC Agenda opened on the 24th of December. You have until February to make a comment or submission. This site has links to treatments being considered at the March meeting of the Pharmaceutical Benefits Advisory Committee.(PBAC) You can find the agenda via pinned posts on this site and have until February 12th to submit consumer comment. Note Well - No drugs or treatments have yet been put forward for Pro
  2. Currently the Pharmaceutical Benefits Scheme provides that Abiraterone (Brand name Zytiga) must be taken with prednisone or prednisolone. At its March 2017 meeting the PBAC approved an application that whilst Abiraterone must be taken with a corticosteroid, the corticosteroid does not necessarily have to be prednisone or prednisolone. Patients and their doctors are now able to choose the corticosteroid that they use with Abiraterone. There has been evidence that corticosteroids other than prednisone or prednisolone may have less side effects or greater benefits.
  3. Last Friday 10 March 2017 the Pharmaceutical Benefits Advisory Committee (PBAC) reached its initial decisions on drugs to go onto the PBS at reduced prices. This included whether to put Xtandi (Enzalutamide) before chemo on the PBS. The company will be told of the result next Friday 17 March 2017. If necessary, negotiations between the PBAC and the company continue for 4 weeks. The final results will be published on the PBAC website 21 April 2017. (If the company is not happy with the result, they have until July 2017 to appeal.)
  4. Details at the top of the page on: JimJimJimJim.com Click this sentence to go there. A gunner is a person who talks a lot about what he's going but doesn't' get around to doing it. "Gunna" (slang) = "going to" This is the last week before the public consultation closes next Wednesday 8 February. The Government is considering listing Enzalutamide (brand name Xtandi) on the Pharmaceutical Benefits Scheme (PBS) before chemotherapy. It's important that Australian men with prostate cancer, their partners,their families and
  5. Some members needed more technological help to find the form and the video. Here 'tis. Cheers. Jim Help get Xtandi (Enzalutamide) on the PBS for use BEFORE chemotherapy Click on this sentence to go straight to the PBAC to fill out the form. Click this sentence if you wish to see a short YouTube video about this. Click on this sentence to read about the drug and the online form. Closing date for comments is Wednesday 8 February 2017
  6. You will have noticed that the other members of our Executive Committee (Alan Barlee, Nev Black, Paul Hobson, Tony Maxwell) make an enormous contribution to our monthly phone-in meetings, to information and discussion posted on our website (JimJimJimJim.com), and to general support of our members by phone, email, and at Face-to-a-name members' meetings. What you may not be aware of is that your Executive Committee also spends much time and effort in advocacy duties on behalf of the group. Below are some advocacy events held during the past year. Please be aware that wh
  7. “Of the cancer medicines being developed, 91% will be targeted therapies, which is likely to make these medicines more expensive. Pressure on budgets will therefore only increase if something is not done now about cancer drug prices.” Clink on this link to read an article in the online newsletter, MJA InSight, about the increasing costs of cancer drugs. Although the article doesn't offer any solutions to the problem, there are some interesting statistics about the number of cancer drugs (for all cancers, not just prostate cancer) that are likely to be on the market within 5 years.
  8. At its November meeting the Pharmaceutical Advisory Committee (PBAC) considered an application to extend the listing of enzalutamide (brand name Xtandi) to include treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have not had prior docetaxel (chemotherapy). The PBAC has released its decision on the application. It is what the PBAC describes as a "1st time decision not to recommend". It's disappointing that the application was not successful but encouraging that the PBAC is asking Astellas to resubmit the application. Here is the full de
  9. Paul Edwards

    Ipilimumab - Severe Side Effects?

    Ipilimumab (brand name Yervoy) is an immunotherapy drug which has been approved for the treatment of melanoma. There are currently clinical trials being conducted to see whether Ipilimumab is effective in treating prostate cancer. The South Australian Medicines Evaluation Panel has provided data to the Pharmaceutical Benefits Advisory Committee about patients treated with Ipilimumab in South Australian public hospitals. Between 1 August 2013 to 8 December 2014, 56 patients were treated with Ipilimumab. 8 of these patients suffered severe refractory colitis as a side effect of their t
  10. At its November meeting the Pharmaceutical Benefits Advisory Committee was considering whether Enzalutamide ( Brand name Xtandi) should be made available on the Pharmaceutical Benefits Scheme (refer to this previous post on the subject) One of the members in last week's teleconference asked when would we know the outcome of that meeting? Today the Pharmaceutical Benefits Advisory Committee published the outcomes from its July meeting. At this rate we won't know the outcomes of their November meeting until April next year. [Edit 18 December 2015 PBAC published its recommendation
  • Create New...